|
| Tuesday, April 11, 2023 |
|
|
億勝生物與郡是深圳簽訂皮耐克®可吸收性敷料在中國大陸的獨家代理協議 |
| 億勝生物科技有限公司（「億勝生物」或「集團」，股份代碼：1061.HK）欣然宣佈，集團全資附屬子公司珠海億勝醫藥有限公司（「億勝醫藥」）與日本郡是株式會社（「郡是」）全資子公司郡是醫療器材（深圳）有限公司（「郡是深圳」）達成合作 more info >> |
|
|
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China |
| Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. ("Essex Medipharma"), has entered into an Agency Agreement ("Agency Agreement") with Gunze Medical Devices (Shenzhen) Ltd. more info >> |
|
| Wednesday, March 8, 2023 |
|
|
亿胜生物公布2022年度业绩 |
| 亿胜生物科技有限公司（「亿胜生物」或「集团」；股份代码：1061.HK）今日公布截至2022年12月31日止的年度财务业绩。 more info >> |
|
|
億勝生物公布2022年度業績 |
| 億勝生物科技有限公司（「億勝生物」或「集團」；股份代碼：1061.HK）今日公布截至2022年12月31日止的年度財務業績。 more info >> |
|
|
Essex Bio-Technology Announces 2022 Annual Financial Results |
Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2022.
more info >> |
|
| Wednesday, February 22, 2023 |
|
|
亿胜生物与复宏汉霖签订治疗年龄相关性黄斑变性全球共同开发及独家许可协议之经修订协议 |
| 亿胜生物科技有限公司（「亿胜生物」或「集团」，股票代码：1061.HK）今日宣布，集团全资附属子公司亿胜生物投资有限公司（「亿胜生物投资」）及珠海亿胜生物制药有限公司（「珠海亿胜」）与上海复宏汉霖生物技术股份有限公司（「复宏汉霖」，股票代码：2696.HK）就2020年10月签订的全球共同开发及独家许可协议（「协议」） 签订一份经修订协议（「经修订协议」）。 more info >> |
|
|
億勝生物與復宏漢霖簽訂治療年齡相關性黃斑變性全球共同開發及獨家許可協議之經修訂協議 |
| 億勝生物科技有限公司（「億勝生物」或「集團」，股票代碼：1061.HK）今日宣布，集團全資附屬子公司億勝生物投資有限公司（「億勝生物投資」）及珠海億勝生物製藥有限公司（「珠海億勝」）與上海復宏漢霖生物技術股份有限公司（「復宏漢霖」，股票代碼：2696.HK）就2020年10月簽訂的全球共同開發及獨家許可協議（「協議」） 簽訂一份經修訂協議（「經修訂協議」）。 more info >> |
|
|
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration |
| Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced that two of its wholly-owned subsidiaries, Essex Bio-Investment Limited ("Essex Bio-Investment") and Zhuhai Essex Bio-Pharmaceutical Co. Ltd ("Zhuhai Essex") more info >> |
|
| Friday, February 10, 2023 |
|
|
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases |
| Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced that the first patient in the United States (US) was dosed in a global multi-centre phase 3 clinical trial (NCT04740671) of EB12-20145P (HLX04-O), a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the Group and Shanghai Henlius Biotech, Inc. more info >> |
|
|
亿胜生物宣布贝伐珠单抗眼科适应症国际多中心III期临床研究完成美国首例患者给药 |
| 亿胜生物科技有限公司（“亿胜生物”或“集团”，股票代码：1061.HK）今日宣布，集团与上海复宏汉霖生物技术股份有限公司（“复宏汉霖”，股票代码：2696.HK）合作开发重组抗血管内皮生长因子（Vascular endothelial growth factor，VEGF）人源化单克隆抗体注射液EB12-20145P（HLX04-O）的国际多中心III期临床研究（NCT04740671）完成美国首例患者给药 more info >> |
|
|
|
|
